Table 1.
Comparison of the patients' characteristics and clinicopathological features between low and high PKM2 expression groups
| Clinicopathological variables | PKM2 expression | ||||
|---|---|---|---|---|---|
| Low | High | P value | |||
| No. | % | No. | % | ||
| Age(years) | |||||
| <50 | 58 | 40.6 | 71 | 46.4 | 0.311 |
| ≥50 | 85 | 59.4 | 82 | 53.6 | |
| Menopausal status | |||||
| pre | 57 | 39.9 | 67 | 43.8 | 0.493 |
| post | 86 | 60.1 | 86 | 56.2 | |
| Family history of cancer | |||||
| yes | 41 | 31.1 | 44 | 31.9 | 0.884 |
| no | 91 | 68.9 | 94 | 68.1 | |
| Tumor size (T stage) | |||||
| T1 | 63 | 45 | 87 | 58.8 | 0.008* |
| T2 | 59 | 42.1 | 55 | 37.2 | |
| T3 | 18 | 12.9 | 6 | 4 | |
| Lymph node stage | |||||
| N0 | 82 | 58.1 | 66 | 43.7 | 0.047* |
| N1 | 31 | 22.0 | 37 | 24.5 | |
| N2 | 11 | 7.8 | 24 | 15.9 | |
| N3 | 17 | 12.1 | 24 | 15.9 | |
| Histological grade | |||||
| Ⅰ | 9 | 6.3 | 10 | 6.6 | 0.886 |
| Ⅱ | 106 | 74.7 | 109 | 72.2 | |
| Ⅲ | 27 | 19 | 32 | 21.2 | |
| ER status | |||||
| NEG | 47 | 33.8 | 51 | 33.3 | 0.931 |
| POS | 92 | 66.2 | 102 | 66.7 | |
| PR status | |||||
| NEG | 66 | 47.5 | 66 | 43.1 | 0.456 |
| POS | 73 | 52.5 | 87 | 56.9 | |
| HER2 status | |||||
| NEG | 123 | 88.5 | 135 | 88.2 | 0.946 |
| POS | 16 | 11.5 | 18 | 11.8 | |
| Ki67 status | |||||
| <20 | 57 | 41.9 | 59 | 39.3 | 0.657 |
| ≥20 | 79 | 58.1 | 91 | 60.7 | |
| Molecular subtypes | |||||
| Luminal A | 55 | 40.4 | 58 | 38.7 | 0.815 |
| Luminal B | 35 | 25.7 | 46 | 30.7 | |
| HER2 enriched | 13 | 9.6 | 14 | 9.3 | |
| Basal like | 33 | 24.3 | 32 | 21.3 | |
| Clinical staging | |||||
| Ⅰ | 38 | 27.5 | 37 | 25.2 | 0.255 |
| Ⅱ | 68 | 49.3 | 62 | 42.2 | |
| Ⅲ | 31 | 22.5 | 44 | 29.9 | |
| Ⅳ | 1 | 0.7 | 4 | 2.7 | |
Lymph node stage: N0, indicates no lymph node metastasis; N1, 1-3 lymph node metastasis; N2, 4-9 lymph node metastasis; N3, ≥10 lymph node metastasis; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor 2; NEG: negative expression; POS: positive expression; Analysis was limited to patients for whom data were available; *indicates P<0.05.